Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SM 3321

Next Previous
X
Search
Drug Profile

SM 3321

Alternative Names: SM-3321

Latest Information Update: 11 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing StarMab BioMed Technology
  • Class Antineoplastics; Immunotherapies; Polyclonal antibodies; Single-domain antibodies
  • Mechanism of Action FCGR3A protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

  • 23 Oct 2023 Beijing StarMab Biomed Technology plans a phase I trial in Acute myeloid leukemia, Multiple myeloma and other hematological malignancies in USA and Australia (Beijing StarMab Biomed Technology pipeline, October 2023)
  • 31 Aug 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06087770)
  • 17 Jan 2023 Preclinical trials in Acute myeloid leukaemia in China (IV), prior to January 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top